alcohol glp 1 GLP-1 Drug Semaglutide Substantially Reduced Heavy Consumption and Weight in Patients with Alcohol Use Disorder and Obesity GLP-1 medications get at the

Presented for research literature review only Sensi B et al

The FDA Adverse Event Reporting System (FAERS) contains reports of musculoskeletal complaints associated with GLP-1 use, but such reports do not prove causation and may reflect coincidental associations or other contributing factors

FIGURE 4 This is complicated because as a polar, charged tripeptide, transport of GSH is significantly inhibited by the blood-brain barrier (BBB), thus limiting effective delivery to brain-resident immune cells such as microglia which are central drivers of neuroinflammatory pathology (Valdovinos-Flores and Gonsebatt, 2012

The backorder of semaglutide has led patients to seek alternatives

doi: 10.1016/j.ymthe.2016.11.020